Epidemiology of Venous Thrombosis and Pulmonary Embolism
静脉血栓形成和肺栓塞的流行病学
基本信息
- 批准号:7002648
- 负责人:
- 金额:$ 30.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-02-01 至 2007-12-31
- 项目状态:已结题
- 来源:
- 关键词:ABO(H) blood groupsantifibrinolytic agentscarboxypeptidasecardiovascular disorder epidemiologycardiovascular disorder riskclinical researchcoagulation factor Vcoagulation factor VIIdisease /disorder etiologyenzyme linked immunosorbent assayfrail elderlyhigh performance liquid chromatographyhomocysteinehormone therapyhuman genetic material taghuman middle age (35-64)human old age (65+)human subjectlongitudinal human studynutrient intake activityobesityprothrombinpulmonary circulation obstructionquestionnairesvenous thrombosisvitamin B6
项目摘要
DESCRIPTION (provided by applicant): Venous thromboembolism (VTE), comprising deep venous thrombosis and pulmonary embolism, is a major contributor to morbidity and mortality in the US. We propose here a 4-year continuation of our unique and informative Longitudinal Investigation of Thromboembolism Etiology (LITE), a prospective study within the ARIC and CHS cohorts. We have several important findings from the previous project period, the three most important being (1) identification for the first time in a prospective study that plasma fibrin fragment D-dimer, a marker of fibrin turnover, is positively and strongly associated with risk of future VTE, (2) verification, again for the first time prospectively, that factor VIII and von Willebrand factor are strong risk factors for VTE, and (3) demonstration that obesity and diabetes are important VTE risk factors, but that most other arterial disease risk factors, including fibrinogen and C-reactive protein, are not. We plan to build upon these findings during LITE continuation, by adding new cases and testing new hypotheses. Our aims are
1. To extend VTE event follow-up in the LITE Study for 4 more years, which is expected to increase the current number of VTE events (n=335) by 47 percent (to n=493), and to sample 1 control per case. In the new cases and controls, we will measure analytes found to be important in LITE already (factor V Leiden, prothrombin G20210A variant, D-dimer, and TAFI), to serve as covariates in combined analyses.
2. To conduct nested case-control studies in the entire sample of 493 VTE cases and 828 controls, using prediagnosis blood and DNA specimens, to determine the prospective associations of VTE with several novel plasma hemostatic factors and genetic markers.
3. To conduct longitudinal analyses of VTE incidence and potential risk factors (or interaction) that we have not yet fully explored: diet, frailty, hormone replacement therapy, and obesity interactions.
4. To study serial blood levels of D-dimer and homocysteine, to better understand their associations with VTE occurrence.
Continuation of this comprehensive prospective study will provide additional important epidemiologic insights into the etiology of VTE. This could lead to new strategies for prevention or treatment of VTE.
描述(由申请人提供):静脉血栓栓塞(VTE),包括深静脉血栓形成和肺栓塞,是美国发病率和死亡率的主要原因。在此,我们建议对我们独特且信息丰富的血栓栓塞病因学纵向调查(LITE)进行为期4年的延续,这是一项针对ARIC和CHS队列的前瞻性研究。我们在之前的项目期间有几个重要的发现,其中最重要的三个是:(1)在前瞻性研究中首次发现血浆纤维蛋白片段d -二聚体(纤维蛋白周转的标志)与未来静脉血栓栓塞的风险正相关,(2)再次前瞻性地首次证实,VIII因子和血管性血血病因子是静脉血栓栓塞的强烈危险因素。(3)证明肥胖和糖尿病是重要的静脉血栓栓塞危险因素,但大多数其他动脉疾病危险因素,包括纤维蛋白原和c反应蛋白,不是。我们计划在LITE继续期间通过增加新病例和测试新假设来建立这些发现。我们的目标是
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AARON R FOLSOM其他文献
AARON R FOLSOM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AARON R FOLSOM', 18)}}的其他基金
TAS::75 0872::TAS CLINICAL EXAMINATION CENTER
塔斯马尼亚州::75 0872::塔斯马尼亚州临床检查中心
- 批准号:
8354878 - 财政年份:2010
- 资助金额:
$ 30.67万 - 项目类别:
CORONARY HEART DISEASE INCIDENCE IN RELATION TO TOTAL HOMOCYSTEINE
冠心病发病率与总同型半胱氨酸的关系
- 批准号:
6592341 - 财政年份:2002
- 资助金额:
$ 30.67万 - 项目类别:
CORONARY HEART DISEASE INCIDENCE IN RELATION TO TOTAL HOMOCYSTEINE
冠心病发病率与总同型半胱氨酸的关系
- 批准号:
6453717 - 财政年份:2001
- 资助金额:
$ 30.67万 - 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTER
亚临床心血管疾病研究--现场中心
- 批准号:
6359445 - 财政年份:1999
- 资助金额:
$ 30.67万 - 项目类别:
CORONARY HEART DISEASE INCIDENCE IN RELATION TO TOTAL HOMOCYSTEINE
冠心病发病率与总同型半胱氨酸的关系
- 批准号:
6116121 - 财政年份:1999
- 资助金额:
$ 30.67万 - 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTER
亚临床心血管疾病研究--现场中心
- 批准号:
6018086 - 财政年份:1999
- 资助金额:
$ 30.67万 - 项目类别:
SUBCLINICAL CARDIOVASCULAR DISEASE STUDY--FIELD CENTER
亚临床心血管疾病研究--现场中心
- 批准号:
6370971 - 财政年份:1999
- 资助金额:
$ 30.67万 - 项目类别:
相似海外基金
Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
- 批准号:
7589884 - 财政年份:2009
- 资助金额:
$ 30.67万 - 项目类别:
Efficacy of Kunitz Domain 1 variants of TFPI-2 as novel antifibrinolytic agents
TFPI-2 Kunitz 结构域 1 变体作为新型抗纤维蛋白溶解剂的功效
- 批准号:
7792289 - 财政年份:2009
- 资助金额:
$ 30.67万 - 项目类别:
Study on antifibrinolytic agents associated with central serous chorioretinopathy
中心性浆液性脉络膜视网膜病变相关抗纤溶药物的研究
- 批准号:
10671639 - 财政年份:1998
- 资助金额:
$ 30.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




